Top

Tag: cell therapy


Cell and Gene Therapy, Industry

Obsidian bags $115M to untether cell therapy from toxic sidekick

September 9, 2021

Via: FierceBiotech

Obsidian Therapeutics has raked in $115 million to realize the long-unfulfilled therapeutic promise of tumor-infiltrating lymphocytes (TILs). The series B gives Obsidian a shot at showing whether freeing TILs from IL-2 can finally unleash power that research has hinted at […]


Mergers and Acquisitions

Roche bets on T-cell therapies with Adaptimmune deal

September 8, 2021

Via: PMLiVE

The deal with see Adaptimmune receive $150m upfront, another $150m over the next five years and then milestone payments potentially exceeding $3bn in aggregate sales, as well as royalties. Unlike other leaders in next-generation cell therapies, the partners will use […]


Cell and Gene Therapy, Industry

Improving CAR-T cell therapy with more sensitive tumor identification

August 25, 2021

Via: FierceBiotech

CAR-T cell therapies, which involve engineering a patient’s own T cells to target and kill cancer cells bearing specific antigens, has shown strong results in blood disorders. But many patients still progress or relapse after initial remission, because tumor cells […]


Cell and Gene Therapy, Industry

Improving Stability for Gene Therapy Products

August 24, 2021

Via: Genetic Engineering and Biotechnology News

Recent interest in gene therapies and the genetic constructs on which they are based is causing a flurry of activity in facility construction and expansion. After they are manufactured doses must be stored, shipped, and stored again as they await […]


Cell and Gene Therapy, Industry

Cell, gene therapy company funding reaches new heights, despite setbacks

August 19, 2021

Via: Biopharma Dive

The amount of money flowing into cell and gene therapy development suggests investor confidence in the field’s future remains high, even as clinical, regulatory and commercial setbacks have hindered a number of companies, such as Bluebird bio, Biogen and Adverum […]


Cell and Gene Therapy, Industry

Innoforce Expands Cell and Gene Therapy Capabilities

August 17, 2021

Via: Contract Pharma

Innoforce Pharmaceuticals has opened a new advanced cell and gene therapy development facility in Hangzhou, China. Analytical development (AD) and process development (PD) represents a critical step towards providing services for potential clients in their cell and gene therapy product […]


Mergers and Acquisitions

Lykan Bioscience and Vineti Partner to Advance Cell Therapies from Clinic to Commercialization

August 13, 2021

Via: Biopharm International

On Aug 12, 2021, Lykan Bioscience, a US-based contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, a US-based enterprise software platform company, announced a partnership that will combine Lykan’s purpose-built, multi-product cell therapy manufacturing facility located […]


Cell and Gene Therapy, Industry

Cell and gene therapy manufacturing services market to value $13.8 billion by 2026

August 11, 2021

Via: European Pharmaceutical Review

New market research states the global cell and gene therapy manufacturing services market will reach $13.8 billion by 2026, expanding at a compound annual growth rate (CAGR) of 12.4 percent from its current value of $7.7 billion (in 2021). The […]


Clinical Trials, Research and Development

Predicting and improving clinical trial enrolment: A problem for psychiatry

August 6, 2021

Via: Pharmaphorum

The reasons behind this problem, however, are rarely studied or understood. Despite this, new strategies devised over the last five years are beginning to reverse the trend, and both reduce stigma and increase awareness to funnel new patients into these […]


Clinical Trials, Research and Development

T-knife bags $110M for raft of cell therapy solid tumor trials

August 2, 2021

Via: FierceBiotech

Investors have flocked to T-knife Therapeutics, which has been taking aim at solid tumors, an area where cell therapies have struggled to perform as well as they have in some blood cancers. Just last year, the biotech raised €66 million […]


Cell and Gene Therapy, Industry

Stem Cell Therapy Alleviates Muscular Dystrophy Symptoms in Compassionate-Use Study

July 28, 2021

Via: Genetic Engineering and Biotechnology News

A compassionate-use study has generated promising results for the potential treatment of muscular dystrophies using mesenchymal stem cells (MSCs) derived from Wharton’s jelly (WJ), a substance found in the umbilical cord. The study, led by doctors at Klara Medical Center […]


Cell and Gene Therapy, Industry

Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy

July 20, 2021

Via: PMLiVE

BlueRock – a Bayer subsidiary – is currently evaluating the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enrol ten patients across the US and Canada, with its primary objective to […]